Please assess the completion status of the following clinical trial:

Trial Title: Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. Between the ages of 18 and 55 years.~2. Patients with relapsing-remitting (Phase I/II) or secondary progressive MS (Phase I) according to published criteria~3. EDSS score between 1 and 5.5.~4. Patients are off-treatment for standard therapies (interferon-beta, glatiramer acetate, natalizumab, mitoxantrone)~5. Patients are able to provide written, informed consent prior to any testing under this protocol, including screening and baseline investigations that are not considered part of routine patient care.~6. Disease duration ≤ 5 years (Only Phase II)~Exclusion Criteria:~1. Diagnosis of secondary-progressive (Phase II) or primary-progressive MS, as defined by published diagnostic criteria.~2. Abnormal screening/baseline blood tests exceeding any of the limits defined~3. Pregnant or breast-feeding female.~4. History or signs of immunodeficiency.~5. Concurrent clinically significant (as determined by the investigators) cardiac, immunological, pulmonary, neurological, renal or other major disease.~6. Splenectomy~7. History of HIV or positive HIV antibody testing~8. Serology indicating active Hepatitis B or C infection.~9. Patients with cognitive impairments who are unable to provide written, informed consent prior to any testing under this protocol, including screening and baseline investigations that are not considered part of routine patient care

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ETIMS 1x10^3 (Type: EXPERIMENTAL): The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10\^3 cells.
- ETIMS 1x10^5 (Type: EXPERIMENTAL): The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10\^5 cells.
- ETIMS 1x10^7 (Type: EXPERIMENTAL): The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10\^7 cells.
- ETIMS 1x10^8 (Type: EXPERIMENTAL): The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10\^8 cells.
- ETIMS 5x10^8 (Type: EXPERIMENTAL): The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 5x10\^8 cells.
- ETIMS 1x10^9 (Type: EXPERIMENTAL): The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10\^9 cells.
- ETIMS 2.5x10^9 (Type: EXPERIMENTAL): The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 2.5x10\^9 cells.
- ETIMS 3x10^9 (Type: EXPERIMENTAL): The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 3x10\^9 cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete